LFWD - Lifeward Ltd. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

LFWD

LIFEWARD LTD.

NASDAQ

$6.67

▲ UP 14.02% (0.82)

KEY STATISTICS

Market Cap$10.52 M

52w High$10.13

52w Low$4.14

Dividend Yield—

Frequency—

P/E-0.48

Volume10.40K

Shares Out.1.61M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joshua Hexter

COMPENSATION 2026

Salary$442,312

Stock Awards$0

Incentive Plan Pay$30,962

All Other Comp.$0

Total$473,274

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 12, 2014

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$10.00

Target Low$10.00

Target Median$10.00

Target Consensus$10.00

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.$7.24M

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2026-02-24	Reverse	1:12
2024-03-15	Reverse	1:7
2019-04-01	Reverse	1:25

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

DCOR

0.00%

804

INSTITUTIONAL OWNERSHIP

SHARES OWNED

65.04%

HOLDERS

TOP 8 OF 26 · RANKED BY POSITION SIZE

Kent Lake Capital LLC

Renaissance Technologies LLC

131.7K sh

$93.72K

Susquehanna International Group, Llp

116.9K sh

$83.16K

Cambridge Investment Research Advisors, Inc.

84.4K sh

$60K

Two Sigma Securities, LLC

81.0K sh

$46.72K

Jane Street Group, LLC

68.6K sh

$39.57K

Bank Of America Corp /De/

63.9K sh

$36.78K

PRICE

$6.67 ▲ UP 14.02% (+$0.82)

OVERLAYS

About Lifeward Ltd.

https://golifeward.com ↗

Lifeward Ltd. designs and markets wearable robotic exoskeletons like ReWalk to help individuals with spinal cord injuries stand, walk, and climb stairs, headquartered in Marlborough, MA.

INDUSTRY

Medical - Devices

A PRODUCT LIFEWARD LTD. IS KNOWN FOR

ReWalk 7 Personal Exoskeleton

The ReWalk 7 Personal Exoskeleton is a wearable robotic device that enables individuals with spinal cord injuries to stand, walk, and navigate stairs with advanced features like cloud connectivity and customizable speeds, advancing mobility soluti...

COMPETITORS

COMPETITOR

MYO COMPARE

Lifeward in 2025

SENTIMENT: − NEGATIVE

EARNINGS · AUGUST 2025

Lifeward's Stock Price Decline Triggers Goodwill Impairment Charge in Q2 2025 Earnings Report

In its second-quarter 2025 financial results, Lifeward Ltd. announced a $2.8 million goodwill impairment charge, which the company stated was triggered by a significant decline in its share price. This event was particularly notable as it came shortly after a new CEO took the helm and involved the company resetting its full-year 2025 financial guidance downwards to between $24–$26 million in revenue.

LEADERSHIP STRATEGY · Q2 2025 · IN PROGRESS

New CEO Implements Strategic Overhaul, Prioritizing Profitability and Operational Excellence

Following the appointment of new CEO Mark Grant in May 2025, Lifeward initiated a significant strategic shift focused on achieving profitability and operational efficiency. This new direction involved resetting full-year 2025 financial guidance to between $24 million and $26 million in revenue and a non-GAAP net loss of $12 million to $14 million, reflecting a more disciplined approach to growth.